Drug interactions and protease inhibitors used in the treatment of hepatitis C: How to manage?

Pharmacokinetic Interaction between Telaprevir and Methadone

(2013) Rolf van Heeswijk et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic Evaluation of the Interaction between Hepatitis C Virus Protease Inhibitor Boceprevir and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Atorvastatin and Pravastatin

(2013) E. G. J. Hulskotte et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Review of drug interactions with telaprevir and antiretrovirals

(2013) Rolf PG van Heeswijk et al.   ANTIVIRAL THERAPY

Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole

(2013) C. T. M. M. de Kanter et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Effect of telaprevir on the pharmacokinetics of sirolimus in liver transplant recipients

(2013) Jacqueline G. O'Leary et al.   LIVER TRANSPLANTATION

Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection

(2012) D. C. Gatti et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Effect of Telaprevir on the Pharmacokinetics of Buprenorphine in Volunteers on Stable Buprenorphine/Naloxone Maintenance Therapy

(2012) Xia Luo et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Practical Management of Boceprevir and Immunosuppressive Therapy in Liver Transplant Recipients with Hepatitis C Virus Recurrence

(2012) Audrey Coilly et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Telaprevir: pharmacokinetics and drug interactions

(2012) Varun Garg et al.   ANTIVIRAL THERAPY

Interaction of the antiviral drug telaprevir with renal and hepatic drug transporters

(2012) Annett Kunze et al.   BIOCHEMICAL PHARMACOLOGY

The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers

(2012) Varun Garg et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Lack of a Clinically Significant Drug–Drug Interaction in Healthy Volunteers Between the Hepatitis C Virus Protease Inhibitor Boceprevir and the HIV Integrase Inhibitor Raltegravir

(2012) Clara T. M. M. de Kanter et al.   CLINICAL INFECTIOUS DISEASES

Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies

(2012) Varun Saxena et al.   Current Opinion in Organ Transplantation

Review and management of drug interactions with boceprevir and telaprevir

(2012) Jennifer J. Kiser et al.   HEPATOLOGY

Safe Coadministration of Raltegravir-Based HAART in HIV-Infected Patients With HCV-Cirrhosis Receiving Triple Therapy With Telaprevir or Boceprevir

(2012) Ana Moreno et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Pharmacokinetic Interaction Between Boceprevir and Etravirine in HIV/HCV Seronegative Volunteers

(2012) Kyle P. Hammond et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Clinical management of drug–drug interactions in HCV therapy: Challenges and solutions

(2012) David Burger et al.   JOURNAL OF HEPATOLOGY

Direct-acting antivirals for hepatitis C virus infections in patients co-infected with human immunodeficiency virus

(2012) Lionel Piroth   Clinics and Research in Hepatology and Gastroenterology

EMA approved new drugs: telaprevir and boceprevir

(2012) Mark Nolan   European Journal of Hospital Pharmacy-Science and Practice

Effect of the Hepatitis C Virus Protease Inhibitor Telaprevir on the Pharmacokinetics of Amlodipine and Atorvastatin

(2011) Jee Eun Lee et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus

(2011) Varun Garg et al.   HEPATOLOGY

An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases

(2011) Marc G. Ghany et al.   HEPATOLOGY

Effect of Telaprevir on the Pharmacokinetics of Midazolam and Digoxin

(2011) Varun Garg et al.   JOURNAL OF CLINICAL PHARMACOLOGY

1244 THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND THE INVESTIGATIONAL HCV PROTEASE INHIBITOR TELAPREVIR

(2011) R. van Heeswijk et al.   JOURNAL OF HEPATOLOGY

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

(2011) Fred Poordad et al.   NEW ENGLAND JOURNAL OF MEDICINE

Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection

(2011) Kenneth E. Sherman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Telaprevir for Retreatment of HCV Infection

(2011) Stefan Zeuzem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Directly acting antivirals for hepatitis C and antiretrovirals

(2011) Kay Seden et al.   Current Opinion in HIV and AIDS

Characterization of Human Liver Enzymes Involved in the Biotransformation of Boceprevir, a Hepatitis C Virus Protease Inhibitor

(2010) A. Ghosal et al.   DRUG METABOLISM AND DISPOSITION

Telaprevir for Previously Treated Chronic HCV Infection

(2010) John G. McHutchison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mécanismes des interactions médicamenteuses d’origine pharmacocinétique

(2009) D. Levêque et al.   REVUE DE MEDECINE INTERNE

The complexities of antiretroviral drug–drug interactions: role of ABC and SLC transporters

(2009) Olena Kis et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Elucidating Rifampin's Inducing and Inhibiting Effects on Glyburide Pharmacokinetics and Blood Glucose in Healthy Volunteers: Unmasking the Differential Effects of Enzyme Induction and Transporter Inhibition for a Drug and Its Primary Metabolite

(2008) HX Zheng et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS